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PKN3 is the major regulator of 
angiogenesis and tumor metastasis 
in mice
Hideyuki Mukai1, Aiko Muramatsu2, Rana Mashud3, Koji Kubouchi4, Sho Tsujimoto4, 
Tsunaki Hongu5, Yasunori Kanaho5, Masanobu Tsubaki6, Shozo Nishida6, Go Shioi7, 
Sally Danno3, Mona Mehruba3, Ryosuke Satoh4 & Reiko Sugiura4
PKN, a conserved family member related to PKC, was the first protein kinase identified as a target 
of the small GTPase Rho. PKN is involved in various functions including cytoskeletal arrangement 
and cell adhesion. Furthermore, the enrichment of PKN3 mRNA in some cancer cell lines as well as 
its requirement in malignant prostate cell growth suggested its involvement in oncogenesis. Despite 
intensive research efforts, physiological as well as pathological roles of PKN3 in vivo remain elusive. 
Here, we generated mice with a targeted deletion of PKN3. The PKN3 knockout (KO) mice are viable 
and develop normally. However, the absence of PKN3 had an impact on angiogenesis as evidenced by 
marked suppressions of micro-vessel sprouting in ex vivo aortic ring assay and in vivo corneal pocket 
assay. Furthermore, the PKN3 KO mice exhibited an impaired lung metastasis of melanoma cells when 
administered from the tail vein. Importantly, PKN3 knock-down by small interfering RNA (siRNA) 
induced a glycosylation defect of cell-surface glycoproteins, including ICAM-1, integrin β1 and integrin 
α5 in HUVECs. Our data provide the first in vivo genetic demonstration that PKN3 plays critical roles in 
angiogenesis and tumor metastasis, and that defective maturation of cell surface glycoproteins might 
underlie these phenotypes.
Protein kinase N (PKN) is a serine/threonine protein kinase with a catalytic domain homologous to protein kinase 
C and a unique regulatory region containing antiparallel coiled-coil (ACC) domains1,2. PKN is composed of 
three isoforms (PKN1, PKN2, and PKN3) derived from different genes in mammals. PKN1 and PKN2 are widely 
distributed in the mammalian tissues1. In contrast, previous reports showed that PKN3 mRNA was almost unde-
tectable in normal adult tissues, but was found upregulated in various cancer cell lines3. PKN was first described as 
a fatty acid- and phospholipid- activated serine/threonine protein kinase and also as a protease- activated protein 
kinase4,5, however, the responsiveness of protein kinase activity to phospholipids and fatty acids in vitro differ in 
each isoform1, and PKN2 and PKN3 are much less responsive to arachidonic acid than PKN13,6. PKN was also the 
first identified effector protein kinase of Rho GTPase, and each PKN isoform has been reported so far to bind to 
various Rho family GTPases in mammalian tissues1,3,7–14. Members of the Rho family of small GTPases are known 
to serve as molecular switches that regulate a diverse set of cellular functions including cell migration, polariza-
tion, adhesion, cell-cycle control, apoptosis, cellular transformation and metastasis15–17. PKN isoforms have been 
postulated to play some roles in the functions of these Rho family GTPases.
So far, there have been accumulated reports about the potential function of PKN isoforms using cultured cell 
experiments such as; involvement in the regulation of cytoskeletal reorganization12,18, cell adhesion19,20, cell-cycle 
regulation21–23, and tumorigenesis24,25. However, only a few organismal level studies elucidating the physiological 
function of PKN in vivo have been conducted. As an example, the Drosophila Pkn protein, single PKN ortholog 
encoded by the Drosophila genome, is required specifically for the migration and adhesion of the epidermal cells 
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during the morphogenetic process of dorsal closure of the embryo, a developmental process in which Rho and Rac 
GTPases have been directly implicated26. Since mammalian PKN isoforms, thus having overlapping expression 
profile and catalytic activity, it is essential for the clarification of the physiological function of each isoform to 
specifically abrogate each signaling pathway in animal level in vivo. With regard to the organismal study for each 
mammalian PKN isoform, only one KO mouse line of PKN1 has been generated, and only abnormal survival and 
selection of B-cells in secondary lymphoid organs have been reported so far in these mice27, without referring to 
the relationship of PKN1 with cell migration or with Rho GTPases. Here we focus on another isoform, PKN3, 
and describe the generation and characterization of the KO mouse line of this isoform. Fibroblastic cells derived 
from PKN3 KO mice have lower cell migration activity, and PKN3 KO mice showed poor growth factor-induced 
angiogenesis and suppression of lung metastasis of B16 melanoma cells injected through tail vein. The relationship 
between the suppression of growth factor-induced angiogenesis and tumor metastasis has not been clarified, but 
the PKN3 KO mouse experiment clearly revealed that the host PKN3 is crucial for tumor metastasis. Therefore, 
targeting PKN3 in host stromal cells has a therapeutic potential for the prevention of cancer metastasis. We also 
discuss the potential relationship between PKN3 and the small GTPase RhoC based on the phenotype induced 
by deficiency of each molecule.
Results
PKN3 distribution in normal adult mouse tissues. PKN1 has been reported to be expressed in almost 
every tissue and is particularly enriched in the spleen, thymus, testes, and brain (PKN1 is approximately 0.01% of 
total protein in the rat brain)28. On the contrary, initial experiment by Northern blotting reported that PKN3 mRNA 
was almost undetectable in normal tissues compared to cancer cell lines3. In order to increase the sensitivity and 
also to permit analysis of PKN3 mRNA expression, real-time quantitative reverse-transcriptase PCR was employed 
with oligonucleotides specific for mouse PKN3 (Supplementary Fig. 1). This analysis was performed on a variety 
of adult mouse tissues and revealed ubiquitous expression, indicating that PKN3 mRNA is not limited to tumor 
cells. Since the expression level of PKN3 protein as well as PKN2 protein in various normal tissues has not been 
reported yet, next we measured the protein amount of all the isoforms of PKN by the immunochemical method 
as shown in Fig. 1d. PKN3 protein is also ubiquitously expressed in normal adult tissues whereas the amount of 
PKN3 is less than that of PKN1 and PKN2 in most of the tissues.
PKN3 KO mice are viable without any obvious phenotype. In order to identify the physiological 
functions of PKN3 expressed in normal tissues, we established a mutant mouse strain deficient in PKN3. The 
targeting vector was designed to replace the exons 17–19 (encoding the catalytic region containing the activation 
loop) by a neomycin-phosphoglycerate kinase (NEO-PGK) cassette (Fig. 1a). TT2 embryonic stem cell clones 
generated by homologous recombination were injected into ICR 8-cell stage embryos to generate chimeric males. 
Heterozygous mice from the F1 generation were intercrossed to generate PKN3 KO mice that were obtained in the 
Mendelian ratio. We checked mice genotypes by Southern blotting and PCR (Fig. 1b,c). The expression of PKN3 
was determined by immunoblotting (Fig. 1e and Supplementary Fig. 2). As expected, tissues from PKN3 KO mice 
did not produce any PKN3 fragment, as assessed by immunoblotting using antibodies against PKN3. Expression of 
PKN1 and PKN2, the other isoforms of the PKN family, was not significantly changed (data not shown). Despite 
general PKN3 deficiency, PKN3 KO mice developed to fertile adults indistinguishable from those of their wild type 
(WT) counterparts. These findings suggest that PKN3 is dispensable for development and growth to the adult stage.
Functional Characterization of embryonic fibroblast from PKN3 KO mice. PKN3 was reported to 
bind to, RhoA, RhoB, and RhoC, the Rho family small GTPases3,13,14, and also bind to GRAF (GTPase-activating 
protein for Rho associated with focal adhesion kinase) and GRAF229 which are suggested to be involved in cytoskel-
etal rearrangement of cells. Actually, PKN3 has been suggested to be involved in cell migration in PC-3 human 
prostate cancer cell line25 and human umbilical vascular endothelial cell (HUVEC)30, by experiments using small 
hairpin RNA (shRNA) or small interfering RNA (siRNA) against PKN3, respectively. In order to confirm and 
further explore the role of PKN3 in regulation of cell motility, embryonic fibroblast cells were isolated from WT 
and PKN3 KO mouse embryos. The embryonic fibroblasts from WT mice express PKN3 as shown in Fig. 1e. PKN3 
KO cells exhibited lower migratory activity under transwell migration assay using a Boyden chamber as compared 
to WT cells (Fig. 2). Inhibition was observed in cell migration induced by various growth factors, suggesting that 
PKN3 is involved in relatively direct regulation of the actin cytoskeleton of primary fibroblastic cells (Fig. 2c).
PKN3 deletion impairs angiogenesis. Since the cell migration of fibroblastic cells and vascular endothe-
lial cells are known to be important in angiogenesis31, and HUVECs express PKN3 as shown in Fig. 1e, we next 
examined the importance of PKN3 in growth factor-mediated angiogenesis using this mouse line. Mouse “aortic 
ring” explants in collagen or matrigel ex vivo are known to induce capillary-like structures32. Then aortic rings, 
isolated from WT and PKN3 KO mice, were treated with each growth factor such as vascular endothelial growth 
factor (VEGF), basic fibroblast growth factor (bFGF), hepatic growth factor (HGF), platelet derived growth fac-
tor (PDGF), and fibronectin, and the number of emerging microvessel sprouts was counted after seven days in 
three-dimensional culture. Aortic rings from PKN3 KO mice showed impaired microvascular sprouting compared 
with WT controls (representative photographs are shown in Fig. 3a, and statistical analysis is shown in Fig. 3b). 
These data provide evidence that PKN3 is involved in the regulation of the growth factor-mediated angiogenesis.
To gain insight into the role of PKN3 during angiogenesis in vivo, we used a corneal micropocket assay33. After 
seven days of exposure to an implanted pellet containing bFGF, corneas of WT mice showed limbic vessel dila-
tion and sprouting (representative photographs are shown in Fig. 4a, and statistical analysis is shown in Fig. 4b). 
In contrast, corneal vessels from PKN3 KO mice showed tendency of minimal bFGF-stimulated sprouting, as 
evidenced by reduction in vessel area (Fig. 4). Despite the deficiency of in vivo angiogenesis in the corneal pocket 
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Figure 1. Generation of PKN3 KO mice. (a) Scheme of PKN3 genomic DNA, targeting vector, and disrupted 
gene. The targeting vector and a partial map of the PKN3 locus before and after homologous recombination in 
ES cells, and after further deletion of neomycin resistance cassette by Cre mediated recombination. Positions of 
the loxP sites are designated by black triangles. Subsequent breeding of heterozygous mice indicated by PKN3 
+ /− generates PKN3 knockout (KO) mice (PKN3 − /− ). The exons, deduced by comparison with the cDNA 
sequence, are denoted by black boxes. The positions of the genomic DNA probes (a,b) used in Southern blotting 
are indicated, as well as the positions of the primers used for screening of homologous recombination (L-Neo1 
and N3-R2), and subsequent PCR genotyping (W-GF, GL, N3-LF7). (b) Southern blot analysis. Shown is the 
result of a representative litter of F2 mice obtained by crossing a pair of PKN3 + /− (containing Neo cassette) 
F1 mice. Genomic DNA was digested with ApaI and probed with probe A on the left, and digested with BamHI 
and probed with probe B on the right. (c) PCR genotyping for discrimination between WT and mutant allele 
lacking Neo cassette. (d) Quantification of PKN3 in various tissues of WT mice. Each tissue was homogenized 
and subjected to SDS-PAGE. The amount of PKN3 was measured by immunoblot analysis using the α NUS 
antibody and indicated as “μ g/g of wet tissue”. The data are expressed as the means ± S.E.M from n = 3 mice.  
(e) Expression of PKN3. Whole-cell lysates of 500 μ g wet weight of each tissue from WT and PKN3 KO mice 
was resolved by SDS-PAGE, and subjected to immunoblot analysis using the α NUS antibody and anti α -tubulin 
antibody. Fifty μ g protein of whole cell lysate of each HUVECs and mouse embryonic fibroblasts was subjected 
to SDS-PAGE followed by immunoblot analysis using the α NUS antibody and anti α -tubulin antibody. White 
arrowhead indicates mouse PKN3. Black arrowhead indicates human PKN3. WT, WT mice; KO, PKN3 − /− 
mice.
www.nature.com/scientificreports/
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assay, PKN3 KO mice developed to the adult stage without obvious vascular deficiencies and developmental 
defects as described above. These results indicate that PKN3 is not needed for normal vascular development but 
supports angiogenesis in some circumstances. This might be due to the successful compensation for the lack of 
PKN3 in mouse development with PKN1 and PKN2 expressed abundantly in mouse tissues, and the extra demand 
of angiogenesis might absolutely require PKN3.
PKN3 KO does not affect tumor angiogenesis. Alterations in aortic ring outgrowth are typically accom-
panied by altered tumor angiogenesis34-36. To determine whether stromal PKN3 expression affects tumor growth 
and angiogenesis, we injected PKN3 KO and WT mice subcutaneously with 1 × 106 Lewis lung carcinoma cells 
and monitored tumor growth over time. Calliper measurements of the tumors showed no significant difference 
in tumor sizes between the WT controls and PKN3 KO mice (Fig. 5a). We next analyzed the blood vessel density 
of the tumors in WT and PKN3 KO mice. Size-matched, 30-day-old tumors from WT and PKN3 KO mice were 
taken and the number and the total length of CD31-positive blood vessels per unit area across entire midline 
sections was assessed. None of the density, total length per unit area, and the average length of each blood vessel 
were significantly different in PKN3 KO mice compared with WT controls (representative CD31 staining images 
are shown in Fig. 5c, and statistical analysis is shown in Fig. 5d), suggesting that PKN3 KO is not sufficient to 
inhibit tumor angiogenesis.
Melanoma metastasis can be restrained in mice lacking PKN3. Tumor derived PKN3 was previously 
reported to be involved in metastasis of PC-3 prostate cancer cells by an experiment using PKN3 shRNA treatment 
of this cell line25. However, it is not clear whether PKN3 in the host stromal cells has a role in tumor metastasis. 
Figure 2. Migration of embryonic fibroblasts from WT and PKN3 KO mice. (a) Cell migration was 
determined using the Transwell membrane. After 5 h of incubation at 37 °C, the cells that had migrated to the 
lower surface of the membrane were fixed and stained. Shown are the representative photos of lower surface of 
the Transwell membrane. (b) Diagrams of migrating cells in the presence of 10% FBS or 5% BSA as a control. 
n = 9. ** indicates P < 0.01. (c) Diagrams of migrating cells in the presence of various migration factors. The 
concentration of migration factors are as follows. Fibronectin, 10 μ g/ml; lysophosphatidic acid (LPA), 10 μ M; 
PDGF, 25 ng/ml; Epidermal growth factor (EGF), 25 ng/ml; bFGF, 20 ng/ml; Nerve growth factor (NGF),  
50 ng/ml; Insulin-like growth factor-1 (IGF-1), 100 ng/ml. P values are as follows. Fibronectin, p = 0.044/n = 9; 
LPA, p = 0.029/n = 4; PDGF, p = 0.035/n = 9; bFGF, p = 0.036/n = 4; IGF-1, p = 0.069/n = 4. * indicates P < 0.05.
www.nature.com/scientificreports/
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Santel et al. have suggested that knockdown of PKN3 by giving the siRNA drug, Atu027, into whole body signif-
icantly suppressed tumor metastasis in mouse model37, which suggests the potential role of host PKN3 in tumor 
progression, whereas clear deprivation of the effect of siRNA on tumor-derived PKN3 seems to be impossible in 
this system. Thus, to clearly assess the role of host PKN3 in tumor metastasis, B16BL6 melanoma cells were injected 
into the tail vein of WT and PKN3 KO mice. Fourteen days later, mice were sacrificed and lungs were observed 
from outside. Suppression of metastases was observed in the lungs of PKN3 KO mice as compared to WT mice 
(Fig. 6a,b). These lungs were dissected and further analyzed microscopically. The lung sections also showed signif-
icantly less number of metastatic foci visible in the lung of PKN3 KO mice as compared to WT mice (Fig. 6c). The 
average size of the metastatic foci was significantly smaller in PKN3 KO mouse lungs than WT lungs (Fig. 6d,e). 
Taken together, these data demonstrated that stromal PKN3 plays important roles in metastasis of melanoma.
Santel et al. presented a hypothesis that the knockdown of PKN3 by RNAi promotes the elevation of 
VE-cadherin, a major protein involved in adherens junction integrity in the vascular endothelial cells, and pre-
vents tumor metastasis through enhancement of this endothelial barrier37. Then we analyzed the expression level 
of VE-cadherin in the lungs of WT and PKN3 KO mice. Immunoblotting of mouse lungs with anti VE-cadherin 
antibody did not show significant difference in the amount of VE-cadherin between WT and PKN3 KO mice 
(Fig. 7a). Next, we biochemically isolated the plasma membrane fraction of lungs from the WT and PKN3 KO mice, 
and examined the expression of VE-cadherin by immunoblotting with anti VE-cadherin antibody. As shown in 
Fig. 7b, there was not a significant difference in the amount of VE-cadherin, either. Immunohistochemical staining 
of mouse lungs with anti VE-cadherin antibody revealed that the number of VE-cadherin-positive large blood 
Figure 3. Influence of PKN3 KO in the regulation of ex vivo angiogenesis. (a) Abdominal aortic ring 
segments from WT or PKN3 KO mice embedded in matrigel (for PDGF) or collagen (for VEGF, bFGF, HGF, 
and Fibronectin). Aortic ring segments were incubated with each growth factor indicated for 6 days. Panel shows 
representative photomicrographs of microvascular sprouting in each condition after 6 days in culture. (b) Effect 
on the sprouting vessels from ex vivo aortic rings. Bars represent mean of 15 independent experiments ± SEM. 
(mouse number of each genotype is 5). * and ** indicate P < 0.05 and P < 0.01, respectively.
www.nature.com/scientificreports/
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vessels was not significantly different between PKN3 KO and WT mice, and that the VE-cadherin-positive small 
blood vessels were rather less in PKN3 KO mouse lung than WT (Fig. 7d).
PKN3 siRNA impairs maturation of some cell-surface glycoproteins. Adhesive interactions of tumor 
cells with the endothelial cells are initial key events in the extravasation of tumor cells from the blood stream to the 
underlying tissue. Firm adhesion of tumor cells with the endothelial cells are mediated by cell adhesion molecules 
such as the Intercellular Adhesion Molecule-1 (ICAM-1) and Vascular Cell Adhesion Molecule-1 (VCAM-1) 
from the immunoglobulin family as well as the integrin family, leading to tumor invasion38,39. Several clinical and 
experimental studies show that high ICAM-1 activity is associated with tumor or metastasis progression whereas 
ICAM-1 depletion leads to reduced metastasis formation40–44. In order to examine the role of PKN3 on the adhesion 
molecules of vascular endothelial cells, PKN3 was knocked down using siRNA in HUVECs. HUVECs transfected 
with mock or with non-target siRNA contained two forms of immunoreactive ICAM-1 separated by SDS-PAGE, 
the ~95 kDa band of ICAM-1 with a less intense ~75 kDa band of ICAM-1 below (Fig. 8a). The ~95 kDa ICAM-1 
immunoreactivity migrated faster from cells treated with PKN3 siRNA than that from control cells (Fig. 8a). 
Pretreatment with λ phosphatase before loading onto SDS-PAGE did not change the migration of the ICAM-1 
immunoreactive band, suggesting that the phosphorylation defect induced by knockdown of PKN3 was not the 
major cause of this band shift (Fig. 8b). To ascertain whether the aberrant ICAM-1 seen after PKN3 siRNA treat-
ment reflected impaired N-glycosylation, lysates of HUVECs were digested with peptide N-glycosidase F (PNGase 
F) before immunoblot analyses. PNGase F is an amidase that removes all saccharide moieties. PNGase F digestion 
completely converted the ~95 kDa ICAM-1 to ~53 kDa species both in PKN3 siRNA treated cells and control 
cells, which equates to the predicted molecular mass of ICAM-1 based on its primary aa sequence (Fig. 8c). These 
results suggest that the faster migration of ICAM-1 immunoreactive band from cells treated with PKN3 siRNA is 
caused by a defect of glycosylation of ICAM-1. Next we examined whether PKN3 depletion affects integrin family 
cell adhesion molecules. HUVECs transfected with non-target siRNA contained two forms of immunoreactive 
integrin β 1 separated by SDS-PAGE, the ~130 kDa band of mature integrin β 1 with a less intense ~110 kDa band 
precursor of integrin β 1 below (Fig. 8d). Integrin β 1 from cells treated with PKN3 siRNA migrated faster than 
that from the control cells in the ~130-kDa glycosylated β 1 band, although the amount of integrin β 1 did not 
differ significantly (Fig. 8d). PNGase F digestion completely converted the ~130-kDa integrin β 1 to a band of 85 
kDa (the size of the core protein) (Fig. 8e). Like ICAM-1 and integrin β 1, integrin α 5, but not integrin α 3, from 
cells treated with PKN3 siRNA migrated slightly faster than that from the control cells. (Fig. 8f). These results 
suggest that PKN3 might be involved in the maturation of some endothelial cell-surface adhesion molecules such 
as ICAM-1, integrin β 1 and α 5.
We do not know the biochemical nature of this effect of PKN3 deficiency on the glycosylation of these endothe-
lial cell-surface proteins. In general, N-linked protein glycosylation takes place in two distinct cellular compart-
ments: the endoplasmic reticulum (ER) and the Golgi apparatus. ER stress seems not to be the main cause of 
Figure 4. Corneal angiogenesis assay of PKN3 KO mice. (a) Corneas of mice 7 days after post implantation 
of growth factor pellets. A hydron pellet containing bFGF was implanted in a surgically created micropocket 
on the cornea of PKN3 KO mice and WT control mice. (b) Angiogenic response quantified by measuring the 
neovascular area in the corneas. Five pairs of animals were used in the study.
www.nature.com/scientificreports/
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Figure 5. Growth of the primary tumor. (a) Growth kinetics of implanted Lewis lung cancer in WT and PKN3 
KO mice. The closed square indicates WT and the open circle indicates PKN3 KO mice. n = 6 mice per group. 
Error bar, SEM. (b) Representative photograph of tumors when resected. (c) Representative photographs of anti 
CD31 antibody staining of tumor sections. (d) The density and the length of blood vessels in tumors. The entire 
field of maximum tumor sections were digitalized by CCD camera and the CD31 staining were traced and 
quantified by using WinROOF (Ver7.2, Mitani corporation, Fukui, Japan) software. Each data point represents 
the mean ± SE. n = 6 mice per group.
www.nature.com/scientificreports/
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Figure 6. Reduced metastasis formation in PKN3 KO mice. (a) Macroscopic appearance of lungs obtained from 
WT and PKN3 KO mice at 14 days after an i.v. injection of B16BL6 cells. (b) The number of metastatic foci on the 
lung surface. ** indicates P < 0.01. (c) Microscopic appearance of lungs after B16BL6 cell injection. Lungs were 
removed at 14 days after injection of melanoma cells, and processed to anti S100 antibody staining to visualize 
melanoma cells and H&E staining. Representative results from independent mice are shown here. (d) The tumor 
size histogram of metastatic foci. The horizontal axis indicates the size of tumor (μ m2) observed in the slice section 
of mouse lungs. The vertical axis indicate the number of foci. (e) The average size of foci of mouse lungs.
www.nature.com/scientificreports/
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Figure 7. Expression of VE-cadherin in WT and PKN3 KO mouse lungs. (a) Immunoblotting of the crude 
extract of mouse lungs with anti VE-cadherin antibody. Each crude extract of lung from individual WT mouse 
(#1 – #3) and PKN3 KO mouse (#1 – #3) was prepared by homogenizing lung directly with sample buffer for 
SDS-PAGE. “α VE-cad” and “α α -tub” indicate immunoblotting with anti VE-cadherin and anti α -tubulin 
antibodies, respectively. (b) Immunoblotting of the plasma membrane fraction of mouse lungs with anti 
VE-cadherin antibody. The plasma membrane fractions of mouse lungs were prepared using Minute Plasma 
www.nature.com/scientificreports/
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altered ICAM-1 N-glycan composition by knockdown of PKN3, since the ~75kDa band of ICAM-1, bearing 
exclusively high-mannose N-glycan structures45, was not affected by introduction of PKN3 siRNA in our experi-
ment (Fig. 8a–c), although ~95 kDa band of ICAM-1, bearing complex N-glycan structures45, was down-shifted 
(Fig. 8a–c). In the Golgi, N-glycans are known to be processed by multiple glycosyltransferases. Among them, 
Golgi N-acetylglucosaminyltransferase V (GnT-V) and III (GnT-III) are two major glycosyltransferases. GnT-V 
promotes the synthesis of a β 1,6-branching GlcNAc structure. However, GnT-III catalyzes the introduction of 
a bisecting β 1,4-GlcNAc residue that inhibits further processing and elongation of the N-glycans catalyzed by 
other glycosyltransferases including GnT-V46. In the case of ICAM-1, the N-glycan composition is reported to 
be modulated by all-trans-retinoic acid by upregulating GnT-III and down-regulating GnT-V via activation of 
the ERK signaling pathway, which causes a significant gel mobility down-shift of the ~95 kDa band of ICAM-147. 
Integrin β 1 is also reported to be a target of GnT-III48 and GnT-V49, and integrin α 5 is shown to be a target of 
GnT-III48. Thus, PKN3 knockdown might inhibit ICAM-1, integrin β 1 and α 5 processing by activation of GnT-III 
or blocking of GnT-V or other glycosyltansferases. PKN3 could be involved in the regulation of gene expression of 
these glycosyltransferases, since PKN family members have been reported to work as regulators for transcription 
activity1,50–52. Another potential mechanism proposes the phosphorylation of the glycosylating enzymes by PKN3 
and modulating their trafficking and substrate access, although most of them are type II transmembrane proteins 
and have a short cytoplasmic tail.
Notably, no obvious down-shift of migration of ICAM-1 immunoreactivity on SDS-PAGE for lung tissue 
extract from PKN3 KO mice was observed (Supplementary Fig. 4) compared to that of wild type mice. The 
possible reasons for the difference of the migration-shift of ICAM-1 on SDS-PAGE between the human cultured 
cells knocked-down of PKN3 and the organ tissues of PKN3 KO mice can be described as follows: i) Multiple 
glycosylation of mouse ICAM-1 masks the migration shift of this protein on the gel (Mouse ICAM-1 shares five 
consensus N-glycosylation sites with human ICAM-1, but comprises additional five N-glycosylation sites in the 
first and fifth Ig domains53). ii) Lung tissue contains many types of cells other than vascular endothelial cells such 
as fibroblasts and macrophages, showing the complexity and heterogeneity of glycan formation (ICAM-1 N-glycan 
content depends on the cell type in which the protein is produced54). The above seeming discrepancy between the 
cultured cells and the organ tissues may also raise the classical question as to whether cultured cells are a reliable 
source for investigating surface glycosylation changes. However, use of such in vitro culture models has given 
some potential insights into the regulation of cell surface glycan expression in previous studies55,56. Therefore, the 
changes of glycosylation of cell surface adhesion molecules should be added to the candidate mechanisms induced 
by PKN3 KO, providing directions to guide further work.
Discussion
This paper represents the first description on the role of PKN3 in angiogenesis and tumor metastasis by establishing 
PKN3 KO mice. We demonstrated that genetic ablation of PKN3 inhibits angiogenesis ex vivo (aortic ring assay) 
and in vivo (corneal micropocket assay) and gives resistance to lung metastasis after tail vein injection of melanoma.
What is the role of PKN3 in angiogenesis? Angiogenesis requires complex interactions of signals and physical 
forces orchestrating the activities of endothelial cells, pericytes, fibroblasts, and smooth muscle cells31. Aleku et al. 
reported that treatment of HUVECs with Atu027, an siRNA-lipoplex directed against PKN3, impaired tube for-
mation on matrigel and migration activity in Boyden Chamber assay and scratch assay30. Our data showed that 
ablation of the PKN3 gene suppressed migration of embryonic fibroblast cells induced by various growth factors 
(Fig. 2). Considering these data, PKN3 is required for efficient angiogenesis, presumably by modulating cell motility 
of angiogenesis-related cells, such as endothelial cells and fibroblastic cells at the actin-cytoskeleton level. However, 
our data showed that PKN3 ablation had no impact on tumor angiogenesis, consistent with the previous report 
describing the orthotopic cancer model treated with Atu027 evaluated by CD31 or CD34 immunoreactivity30. So, 
why does PKN3 appear not necessary during tumor angiogenesis? One possible explanation would be that other 
PKN isoforms could compensate for the loss of PKN3 function in the context of tumor. PKN1, in particular, might 
be stimulated in the stromal cells inside of a tumor, because ischemic/hypoxic stress, which frequently happens 
inside of a tumor, is reported to activate or enhance the expression of PKN157–60.
To obtain information on the possible target point of PKN3 in angiogenesis, we next focused on the glyco-
sylation events of several important cell surface proteins involved in angiogenesis such as integrin, because the 
initiation of angiogenesis by proangiogenic growth factors depends on interactions between the endothelium 
and various extracellular matrix proteins mediated by integrins61. The β 1 integrin in endothelial cells is known to 
participate in angiogenesis with various partner α integrins, and α 5β 1 integrin binds fibronectin, contributing 
Membrane Protein Isolation Kit (Invent Biotechnologies, Inc.). “α VE-cad” indicates immunoblotting with anti 
VE-cadherin antibody. “CBB” indicates Coomassie staining of the gel after SDS-PAGE. (c) Immunohistochemical 
staining of mouse lungs with anti VE-cadherin. Blood vessels were classified into dense (indicated by + ), 
moderate (indicated by + /− ), and weak (indicated by − ) immunoreactive staining groups. (− ) indicates no 
immunoreactivity or indistinguishable from red blood cells. (+ /− ) indicates mild immunoreactivity detectable 
only at x 400 magnification. (+ ) indicates obvious immunoreactivity detectable even at x 100 magnification. 
(d) The number of blood vessels classified by the VE-cadherin immunoreactivity. Blood vessels were first 
classified into two groups by size (“small vessels” and “large vessels”), and further classified by VE-cadherin 
immunoreactivity as described in (C). “small vessels” indicate thin vessels in the peripheral in the intra or inter 
alveolar area. “large vessels” indicate thick vessels rich in tunica media along bronchus or vessels radiating from 
that thick vessel to periphery. “small vessels” were counted up to 100/each slice of lung, and all of the “large 
vessels” were counted in each slice. ** indicates P < 0.01.
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Figure 8. Immunoblotting of HUVECs with antibody against surface glycoproteins. “con siRNA” indicates 
validated universal negative control SIC-001 (Sigma-Aldrich Japan K.K.). “PKN3 siRNA-a” indicates Hs_
PKN3_8290 (Sigma Aldrich Japan K.K.) derived from the coding sequence for ACC3 domain of human PKN3, 
“PKN3 siRNA-b” indicates Hs_PKN3_8291 (Sigma-Aldrich Japan K.K.) derived from the coding sequence 
for the catalytic domain of human PKN3, and PKN3 siRNA-c indicates M-004647-01 (Dharmacon Research) 
derived from the coding sequence for the catalytic domain of human PKN3. (a) Immunoblotting of HUVECs 
transfected with siRNA for PKN3 and control with antibody against ICAM-1 and PKN3. α NUS antibody was 
used for α PKN3 blotting. The arrow indicates the position of PKN3. (b) The effect of treatment of HUVEC 
extract with λ phosphatase on ICAM-1 immunoreactivity. (c) The effect of treatment of HUVEC extract with 
PNGase F on ICAM-1 immunoreactivity. (d) Immunoblotting of HUVECs transfected with siRNA for PKN3 
and control with antibody against integrin β 1. (e) The effect of treatment of HUVEC extract with PNGase F on 
integrin β 1 immunoreactivity. (f) Immunoblotting of HUVECs transfected with siRNA for PKN3 and control 
with antibody against integrin α 3 and α 5.
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to an angiogenesis pathways62. Among the integrins we examined, integrin β 1 and α 5 showed faster migration 
in SDS-PAGE in HUVECs transfected with PKN3 siRNA, suggesting a glycosylation defect of these proteins 
in HUVECs knocked-down of PKN3 (Fig. 8d,f). The alterations in the oligosaccharide portion of integrins are 
reported to regulate cell phenotypes63,64. The function of β 1 integrin depends on its accurate glycosylation. Actually, 
N-glycosylation of integrin α 5β 1 plays a crucial role in cell spreading, cell migration, ligand binding, and dimer 
formation65. Therefore, poor angiogenesis in PKN3 KO mice might be explained by the alteration of glycosylation 
of these integrins.
The next important question would be the cause of the reduction of metastatic foci in the PKN3 KO mouse 
lung. Leenders et al. demonstrated that induced knockdown of PKN3 expression in PC-3 prostate cancer cells by 
shRNA interferes with formation of lymph node metastasis in an orthotopic mouse prostate tumor model, sug-
gesting that PKN3 in tumor cells may primarily be required for metastatic growth of these cells25. Here, we present 
in vivo genetic evidence that PKN3 in stromal cells play important roles in metastasis as evidenced by significantly 
smaller number and the smaller size of the metastatic tumor foci in the lungs of PKN3 KO mice than WT mice 
(Fig. 6). The potential difference of angiogenic activity between WT and PKN3 KO mice does not seem to cause 
this difference, because the tumor diameters were overall less than 1 mm at the time point of mouse dissection 
(14th day after the tumor injection), and the PKN3 KO mice did not show suppression of tumor angiogenesis from 
our subcutaneous tumor implant experiments (Fig. 5). The difference in number and size of the metastatic tumors 
may arise from the substantial disturbance of tumor cell extravasation in PKN3 KO mice than in WT control. If so, 
what is the potential mechanism of the block of tumor cell extravasation in PKN3 KO mice? Santel et al. reported 
that HUVECs knocked down of PKN3 by siRNA revealed elevated levels of VE-cadherin by immunoblotting and 
confocal microscopy37. Furthermore, Atu027-treated mice showed the elevated expression of VE-cadherin in pul-
monary blood vessels in lung, suggesting that the reduction of the intravasation and extravasation of tumor cells by 
increasing the endothelial adherens junction composed of VE-cadherin37. Notably, however, our immunoblotting 
and immunohistochemical analysis (Fig. 7) did not reveal the overexpression of VE-cadherin in PKN3 KO mouse 
lung tissues, even with clear metastatic foci of melanoma. We also evaluated the vascular permeability in the Lewis 
lung cancer tissues reported in Fig. 5 by using the immunoreactivity of fibrinogen/fibrin around blood vessels as 
an endogenous indicator66–68 (Supplementary Fig. 5). This experiment showed that the vascular permeability of 
PKN3 KO mice was not significantly different from that of WT mice. Together with our data about VE-cadherin 
expression levels (Fig. 7), the impairment of lung metastasis of melanoma in PKN3 KO mice may not be simply due 
to the stable elevation of the endothelial barrier in PKN3 KO mice. The reversible endothelial cell retraction is an 
important process in tumor cell extravasation69, therefore the mobility defect of the stromal cells such as endothe-
lial cells in PKN3 KO mice might inhibit the tumor cell extravasation. Additional feature observed in HUVECs 
knocked down of PKN3 was defective glycosylation of ICAM-1 (Fig. 8), a central adhesion molecule important for 
binding and signaling between vascular endothelial cells and tumor cells during the tumor metastasis. The various 
functions of ICAM-1 appear to be differentially regulated by N-linked glycosylation70. Furthermore, it has been 
recently reported that glycosylation deficiency of ICAM-1 hinders cell adhesion and trans-endothelial migration 
of hematological cells47,71. Therefore, the glycosylation defect of ICAM-1 might be involved in the inhibition of 
tumor cell extravasation in PKN3 KO mice.
What is the immediate upstream regulator of PKN3 in angiogenesis and tumor metastasis? PKN3 has been 
reported to bind to RhoA, RhoB, and RhoC small GTPases, showing preferred association with RhoC14. We also 
confirmed that PKN3 selectively binds to the GTP-bound form of RhoC, but not to the GDP bound form or the 
effector domain mutant of RhoC (Supplementary Fig. 6), whereas Hutchinson et al. reported that PKN3 are likely 
targets for RhoB rather than RhoA or RhoC on the basis of affinity by direct binding experiments13. Notably, RhoC 
is reported to be essential for angiogenesis and the downstream regulator of VEGF in endothelial cells by a matrigel 
plug assay using nude mice treated with RhoC-RNAi retrovirus and a tube formation assay of a human dermal 
microvascular endothelial cell line (HMEC-1) in three-dimensional matrigel72. Hakem et al. generated RhoC KO 
mice and demonstrated that the loss of RhoC does not affect tumor development but drastically inhibits tumor 
metastasis, whereas RhoC was absent both in the host and in the tumor cells in their mouse model73. Intriguingly, 
they also showed that deficiency of RhoC does not affect tumor angiogenesis by investigating the levels of CD31 
and Factor VIII expression in primary tumors in their mouse model73. Assuming that PKN3 is the direct target 
of RhoC in stromal cells, the above reports seem to be consistent with our data showing that PKN3 is involved in 
potential angiogenic activity and that PKN3 KO in stromal cells inhibits metastasis but not primary tumor growth 
and in vivo tumor angiogenesis.
The shRNA knockdown of PKN3 in an orthotopic PC-3 prostate cancer model had a profound effect on primary 
tumor growth14, whereas an earlier report had demonstrated the relatively small effect on primary tumor growth 
using the same cancer cell line25. Thus it is still promising that in some conditions PKN3 blocker suppresses the 
primary cancer growth in a cell autonomous-fashion. With regard to the metastasis of cancer, previous studies14,25,74 
consistently support the suppressive effect of the PKN3 blocker on the metastasis in a cell autonomous-fashion, 
and our study also confirmed the suppressive effect in a non-cell autonomous fashion. Therefore, it is conceivable 
that PKN3 blocker would target both tumor cells and stromal cells when used as a potential cancer therapy.
We have demonstrated, the critical role of PKN3 in stromal cells in regulation of tumor metastasis. The expres-
sion profile of stromal PKN3 might act as a prognostic marker of cancer. Our results also indicate PKN3 as a 
possible regulator of neovascularisation and provide a novel insight into the molecular control of angiogenesis. We 
speculate that PKN3 blocking strategies not only could be applied in cancer treatment, but also for other vascular 
diseases such as arthritis and age-related macular degeneration75.
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Methods
Generation of PKN3 KO mice. A genomic fragment of the mouse PKN3 gene was isolated from mouse 
BAC library RPCI-23 (C57BL/6). For disruption of PKN3, a replacement-type targeting vector was first made 
(Fig. 1a). It contained a ~8 kbp SalI–NotI DNA fragment including exon 3-exon 16 of PKN3, neomycin selection 
cassette, and a ~4 kbp XbaI/NheI DNA fragment including exon 20-exon 22 and followed by the diphtheria toxin 
(DT) gene for negative selection. TT2 embryonic stem (ES) cells were transfected with the linearized targeting 
vector by electroporation76. Two of the 192 G418-resistant ES cell clones carried a correctly targeted PKN3 allele, 
as assessed by PCR analysis and Southern blot analysis of genomic DNA. The ES clone was injected into ICR 8-cell 
stage embryos for generation of chimeric mice. A high percentage male chimeric mice, as judged by the agouti coat 
color, were mated with C57BL/6 mice to determine germline transmission. F1 mice were crossed with EIIa-cre 
transgenic mice77 to remove neomycin selection cassette, and were backcrossed at least 16 times into the Charles 
River C57BL/6N background before phenotypic analysis. PKN3 KO mice carrying the homozygous deletion (PKN3 
− /− ) were viable, born at a frequency expected for Mendelian inheritance. PKN3 mouse line has been registered 
as Accession No. CDB0457K: http://www.clst.riken.jp/arg/mutant%20mice%20list.html.
Genotyping and preparation of antibodies. See method section of Supplementary Information.
Animals. This study was approved by the Kobe University and Kinki University Animal Care and Use 
Committees and carried out according to the institutional animal experimentation regulations.
Cell culture and siRNA transfection. B16 melanoma BL6 cells (B16BL6 cells) were supplied by Dr. Inufusa 
(Kinki University, Osaka, Japan) and cultured in RPMI 1640 medium (Sigma) supplemented with 10% fetal calf 
serum (FCS) (Gibco, Carlsbad, CA, USA), 100 μ g/ml penicillin (Gibco), 100 U/ml streptomycin (Gibco), and 
25 mM HEPES (pH 7.4; Wako, Tokyo, Japan) in an atmosphere containing 5% CO2. Lewis lung cancer cells were 
obtained from Riken Cell Bank (Ibaraki, Japan), and cultured in Dulbecco’s Modified Eagle’s medium (Sigma, St. 
Louis, MO, USA) supplemented with 10% FCS (Gibco), 100 μ g/ml penicillin (Gibco), 100 U/ml streptomycin 
(Gibco), and 25 mM HEPES (pH 7.4; Wako, Tokyo, Japan) in an atmosphere containing 5% CO2. HUVECs were 
purchased from Lonza. HUVECs were cultured in EC growth medium (EGM-2 BulletKit, Lonza) supplemented 
with 2% fetal bovine serum (FBS). For RNA-mediated interference of PKN3 expression, the following siRNAs 
were used: Hs_PKN3_8290 (Sigma-Aldrich Japan K.K.), Hs_PKN3_8291 (Sigma-Aldrich Japan K.K.), and siG-
ENOME SMARTpool Human PKN3 M-004647-01 (Dharmacon Research). SIC-001, a validated universal neg-
ative control provided by Sigma-Aldrich Japan K.K., was used as the negative control siRNAs that do not target 
any mammalian gene. Cells cultured in a 6-well plate were transfected with 10 nM siRNA with Lipofectamine 
RNAiMAX (Invitrogen) or Lipofectamine 3000 (Invitrogen). Similar results were obtained in either case of using 
Lipofectamine RNAiMAX (Invitrogen) or Lipofectamine 3000. For immunoblot analysis, cells were lysed by 
scraping into SDS-sample buffer.
Mouse embryonic fibroblasts derived from E14 embryos were prepared according to standard procedures, 
and maintained in DMEM.
Immunoblot analysis. Samples were subjected to 6%–10% SDS-PAGE and separated products were subse-
quently transferred to a polyvinylidene difluoride membrane. The membrane was then blocked with TBS (20 mM 
Tris/HCl at pH 7.5, 137 mM NaCl) containing 0.05% Triton X-100 (TBS-T) and 5% normal goat serum or Blocking 
One (nacalai tesque, Japan) for 1 hr at room temperature. The membrane was then incubated in TBS-T and the 
primary antibody for 1 hr at room temperature or for O/N at 4 °C. The membrane was washed three times (5 min 
each time) in TBS-T before incubating the blot in TBS-T containing the secondary antibody conjugated to horse-
radish peroxidase at 1:2000–1:10000 dilution for 45 min. After this incubation, the membrane was subjected to 
three 10 min washes in TBS-T. Blots were developed by the enhanced chemiluminescence method.
Quantification of PKNs. Mouse tissues were removed quickly after decapitation and added to 9 vol of 50 mM 
Tris/HCl, pH 7.5, containing 5 mM EDTA, 5 mM EGTA, 0.5 mM dithiothreitol (DTT), 10 μ g/ml leupeptin, and 
1 mM phenylmethylsulfonylfluoride (PMSF), and homogenized with 10 strokes of a Teflon/glass homogenizer. 
The crude lysates of various tissues were used for quantification of PKNs by densitometric analysis of immunore-
activity of PKNs on Western blotting using α C6 antibody (for PKN1), α ParN2 antibody (for PKN2), and α NUS 
antibody (for PKN3) as described previously28. Various amounts (1–10 ng) of the purified GST-fused C-terminal 
310 aa region of mouse PKN1, GST-fused N-terminal 506 aa region of mouse PKN2, and GST-fused N-terminal 
125 aa region of mouse PKN3 were used as standards of quantification for PKN1, PKN2, and PKN3, respectively.
Immunohistochemistry. The lungs and isolated tumors were fixed in 4% paraformaldehyde buffered with 
PBS (pH 7.2) and embedded in paraffin. Four-micrometer-thick sections were stained with primary antibodies as 
indicated in each figure, and the immune complexes were visualized by HISTOFINE Simple Stein Mouse MAX-PO 
kit suitable for individual primary antibody (Nichirei Corporation, Tokyo) and 3-3′ Diaminobezidine-4HCl (DAB) 
according to the manufacturers’ instructions.
In vitro migration assay. Migration was analyzed by Boyden chamber assay using Transwell cell culture 
inserts (8.0 μ m pore size; Costar, Cambridge, MA). Adjusted viable cell concentration was counted with trypan 
blue exclusion. Mouse embryonic fibroblasts were plated (5 × 105 cells/ml in serum-free DMEM) in the upper 
chamber. The lower chamber containing various growth factors indicated in the figure legend. After 5 h, the cells 
remaining on the upper surface of the membrane were wiped off, and cells migrating to the lower surface in 
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triplicate wells were visualized with Diff-Quick stain (Sysmex, Japan) and counted in each of four randomly chosen 
light microscopic fields at × 20 objective.
In vivo Tumor Growth Study. Freshly cultured Lewis lung cancer cells resuspended in sterile 1 × PBS and 
1 × 106 cells per 100 μ l were injected subcutaneously between the shoulder blades of approximately 10-week-old 
female WT and PKN3 KO mice (six mice per condition). Tumors were measured every 5 days using Vernier cali-
pers and volume calculated (length × width2 × 0.52). After 30 days, tumors were collected, and were fixed in 4% 
paraformaldehyde for histologic analysis.
Experimental metastasis of tumor cells. B16 BL6 cells (1 × 105 cells in 0.2 ml) were injected into the tail 
vein of 10-week-old female WT and PKN3 KO mice after viable cells were counted with trypan blue exclusion. The 
mice were anesthetized with pentobarbital and sacrificed at 14 d after the cell injection. Subsequently, their lungs 
were excised and fixed in a paraformaldehyde solution. Nodules visible from outside as black forms in the lungs 
were then enumerated. Then the 10 step slice sections with 20 μ m intervals were prepared from each mouse lung 
and were stained with anti S100p antibody, and the analyzed numbers and areas of tumors were measured using 
image analysis software (Motic Image plus 2.5; SHIMADZU, Kyoto, Japan).
Aortic ring assay. Aortic ring assay was carried out as described in78. Briefly, thoracic aortas were isolated from 
WT and PKN3 KO mice under a dissecting microscope, cut into 1-mm sections, and embedded in 24-well plate 
collagen (Nitta gelatin type I-A) or matrigel (Becton Dickinson Biosciences) -coated plates. Medium containing 
2% fetal bovine serum and 30 ng/ml VEGF (VEGF164, ORFgen) or 25 ng/ml PDGF (Peprotech) or 20 ng/ml HGF 
(Peprotech) or 30 ng/ml bFGF (Peprotech) was added to each well of gelled collagen (in case of VEGF, HGF, and 
bFGF) or matrigel (in case of PDGF). The plates were incubated at 37 °C in a 5% CO2 incubator. Microvessel-like 
properties of sprouting structures were observed under microscope.
Corneal micropocket angiogenesis assay. Corneal angiogenesis was assessed as described33. Briefly, cor-
neal micropockets were created using a Mani Ophthalmic Knife in one side eye of 9–10 week-old mice. Micropellets 
containing 80 ng bFGF were implanted into each corneal pocket at 0.8 mm from the limbus. After 7 days, the 
eye was viewed under a dissecting microscope. Finally, vessel area (VA, mm2) was calculated using the formula 
VA = 0.02 π × VL × CH, where VL is the vessel length (in tenths of millimeters) and CH is the clock hours33.
Preparation of HUVEC extract and phosphatase and glycosidase treatment. For λ phosphatase 
treatment, HUVECs from one well of six-well plates were lysed in 100 μ l of cold lysis buffer (50 mM Tris/HCl at 
pH 7.5, 100 mM NaCl, 0.1% Brij 35, 5 mM EGTA, 2 mM DTT, 1 mM PMSF, 10 μ g/ml leupeptin) and homogenized 
using 27 Gauge syringe. After centrifugation at 4 °C at 13,000 × g for 15 min, 30 μ l of the supernatant was incubated 
at 30 °C for 1 hr with/without 2 mM MnCl2 and λ phosphatase (New England Biolabs) as indicated in the figure. The 
resultant sample was subjected to immunoblotting. For PNGase F treatment, HUVECs from one well of six-well 
plates were lysed in 100 μ l of cold lysis buffer (50 mM Tris/HCl at pH 7.5, 150 mM NaCl, 1 mM DTT, 1 mM EDTA, 
0.1% Triton X-100, 5 μ g/ml leupeptin) and homogenized using 27 Gauge syringe. After centrifugation at 13,000 × g 
for 15 min at 4 °C, 5 μ l of the supernatant was incubated with 1 μ l of 10 × glycoprotein denaturing buffer (New 
England Biolabs) and 4 μ l of H2O at 95 °C for 5 min, then chilled on ice. This total reaction was mixed with 2 μ l 
of 10 × G7 reaction buffer, 2 μ l of 10% NP-40, and 6 μ l of H2O, and with/without 1 μ l of PNGase F (New England 
Biolabs) as indicated in the figure. The resultant sample was subjected to immunoblotting.
Statistical analysis. All experiments were performed independently in at least triplicate and a Student’s t-test 
was used to examine the differences between the two groups of data. Differences with p < 0.05 were considered 
statistically significant.
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